| Systemic Lupus Erythematosus Research | Lifetime | 26 | IT 3 | 99.79 |
| Systemic Sclerosis and Related Diseases | Lifetime | 39 | IT 3 | 99.54 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 58 | IT 2 | 99.39 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 351 | IT 6 | 99.32 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 44 | IT 2 | 99.19 |
| Pregnancy and Medication Impact | Lifetime | 104 | IT 4 | 98.44 |
| Biomarkers in Disease Mechanisms | Lifetime | 53 | IT 12 | 97.26 |
| Inflammasome and immune disorders | Lifetime | 182 | IT 13 | 98.01 |
| Reproductive System and Pregnancy | Lifetime | 416 | IT 18 | 97.78 |
| Liver Diseases and Immunity | Lifetime | 214 | IT 19 | 98.18 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 597 | IT 37 | 97.67 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 451 | IT 40 | 97.22 |
| Eosinophilic Disorders and Syndromes | Lifetime | 447 | IT 43 | 96.78 |
| Renal Diseases and Glomerulopathies | Lifetime | 653 | IT 46 | 97.17 |
| Spondyloarthritis Studies and Treatments | Lifetime | 360 | IT 31 | 96.52 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 760 | IT 79 | 94.69 |
| Skin Diseases and Diabetes | Lifetime | 278 | IT 20 | 92.22 |
| Vasculitis and related conditions | Lifetime | 969 | IT 69 | 92.52 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 414 | IT 34 | 89.71 |
| Pericarditis and Cardiac Tamponade | Lifetime | 755 | IT 69 | 85.84 |
| Protein Tyrosine Phosphatases | Lifetime | 878 | IT 56 | 86.33 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 579 | IT 43 | 78.56 |
| Hypertrophic osteoarthropathy and related conditions | Lifetime | 403 | IT 28 | 39.72 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 17 | IT 2 | 99.38 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 61 | IT 11 | 97.33 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 86 | IT 10 | 97.71 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 256 | IT 10 | 95.55 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 220 | IT 24 | 96.55 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 107 | IT 13 | 94.57 |
| Inflammasome and immune disorders | 2021-2025 | 291 | IT 15 | 91.04 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 202 | IT 8 | 90.88 |
| Liver Diseases and Immunity | 2021-2025 | 262 | IT 34 | 91.06 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 386 | IT 64 | 86.15 |
| Pregnancy and Medication Impact | 2021-2025 | 427 | IT 20 | 83.55 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 491 | IT 56 | 86.66 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 957 | IT 75 | 85.40 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 447 | IT 10 | 76.77 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 254 | IT 33 | 77.82 |
| Dermatological and COVID-19 studies | 2021-2025 | 428 | IT 99 | 63.16 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 970 | IT 64 | 62.40 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 731 | IT 60 | 60.86 |
| Skin Diseases and Diabetes | 2021-2025 | 346 | IT 39 | 59.78 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 424 | IT 48 | 59.38 |
| Dermatological and Skeletal Disorders | 2021-2025 | 817 | IT 120 | 40.56 |
